Johnson & Johnson is suspending sales forecasts for its COVID-19 vaccine only a few months after saying the shot could bring in as much as $3.5 billion this year. The health care giant said Tuesday that a supply surplus and demand uncertainty prompted the move. J&J’s one-shot vaccine brought in $457 million in global sales during the first quarter, with most of that coming from outside the United States. The vaccine brought in only $75 million in U.S. sales. That's less than what it rang up after debuting in last year’s quarter.
This item is available in full to subscribers.
We have recently launched a new and improved website. To continue reading, you will need to either log into your subscriber account, or purchase a new subscription.
If you are a digital subscriber with an active subscription, then you already have an account here. Just reset your password if you've not yet logged in to your account on this new site.
If you are a current print subscriber, you can set up a free website account by clicking here.
Otherwise, click here to view your options for subscribing.
Please log in to continue |
